No lawful ranking of 7-hydroxymitragynine (7-OH) products exists in a health sense. FDA says there are no FDA-approved 7-OH drugs. And the agency's position is that 7-OH may not be included in supplements or added to conventional foods. So when a product page tells you why it's better than the rest, most of what it says can't be checked, and some of it is contradicted by the agencies that regulate the category.
The legal ground is also moving. When this list was put together in late October 2026, DEA still hadn't issued its temporary 7-OH order. Under its October 14 notice of intent, publication can't happen before November 13, 2026, and the order would bind from that publication day onward. A search of DEA's latest Federal Register filings will tell you whether that has happened since. None of this is legal advice.
Here are six claims you'll see often, and why each one tells you less than it seems to.
1. "FDA approved" or "FDA registered"
Discount this one first. FDA states plainly that there are no FDA-approved 7-OH drugs, and its July 29, 2025 announcement recommended scheduling certain 7-OH products. An "FDA approved" badge on a 7-OH product is simply untrue.
"FDA registered" is subtler, and it's built to sound similar. Some facilities do register with FDA, but FDA's consumer page "Is It Really 'FDA Approved'?" says registration of an establishment "does not denote approval." The same page says FDA doesn't approve dietary supplements at all. A registration number tells you a facility filed paperwork. It says nothing about whether the product inside the package is lawful.
FDA's own page on these products is titled Hiding in Plain Sight: 7-OH Products. That's not the language an agency uses about something it has signed off on. If a seller leads with FDA's name, read it as a sign the seller either misunderstands the rules or hopes you do.
2. "Legal in all 50 states"
This claim was false before the federal notice, and it's still false now. The DEA's October notice itself lists 10 states that prohibit 7-OH, from Alabama and Arkansas to Vermont and Wisconsin.
Another 19 states allow some leaf kratom but put limits of one kind or another on concentrated or synthetic 7-OH. Texas caps 7-OH at 2% of total alkaloids. Oklahoma caps it at 1%. Georgia caps it at 0.5 mg per gram. And since August 18, 2026, Florida's emergency rule 2ER26-2 has listed 7-OH in Schedule I once it passes 1 mg/g in a solid or 1 mg/mL in a liquid.
Cities add another layer. A state without a ban can still contain one at the city level: Naperville, Illinois has barred retail sales since October 1, 2026. And DEA says federal action won't preempt more restrictive state law. A seller who claims universal legality hasn't checked, and that tells you how much else it hasn't checked.
3. "Lab tested," with no batch COA
"Lab tested" is a claim about a process. It isn't evidence. What counts is a certificate of analysis (COA) for the batch you'd actually receive, and a COA describes one sample from one batch. The batch or lot number on the report has to match the package, or the report describes some other product.
A useful COA reports mitragynine, 7-OH and mitragynine pseudoindoxyl (MP). Under DEA's ratio test, mitragynine is weighed against 7-OH, or against 7-OH and MP together, so a report that never measured MP leaves part of the calculation blank. Read the codes carefully as well. ND is shorthand for below the detection limit, which isn't a reading of zero.
Check the lab as well. If it claims ISO/IEC 17025 accreditation, you can confirm that in the A2LA or ANAB directories. For the layout of a report and how its units convert, 7OH.com's lab report guide walks through the columns that matter. My rule is simple: no matching batch COA, no further consideration.
4. "Natural"
"Natural" has no formal definition in this context. FDA has never set one by rule. Its longstanding food-labeling policy reads the word as meaning nothing artificial or synthetic has been added, and FDA says that policy wasn't meant to address health or nutritional benefits.
The word is especially weak for 7-OH. FDA's figures put 7-OH below 2% of a natural leaf's total alkaloids, and the agency calls it a concentrated byproduct of the plant. So a product sold on its 7-OH content isn't leaf in the ordinary sense. Mitragynine, the main leaf alkaloid, is a separate compound, and the DEA notice doesn't schedule it or the plant.
Leaf itself isn't cleared either. FDA advises consumers against using kratom at all, pointing to serious adverse events such as liver toxicity and seizures. Separate FDA warnings have concerned kratom contaminated with heavy metals or Salmonella. A plant origin doesn't make a product safe, according to the agency that regulates it.
5. "Won't show up on a drug test"
Ignore this claim entirely. A seller has no way to know which test you might face or what it screens for. Labs offer dedicated kratom testing: Labcorp's test 791750, for example, is a urine screen with confirmation that reports both mitragynine and 7-hydroxymitragynine by name.
So a promise about any test is a guess dressed as a fact. If you want to understand what standard drug panels actually look for, that reference explains which panels include kratom alkaloids, and it deliberately gives no detection times. That's the right approach.
There's a legal angle as well. Where 7-OH is already Schedule I, as in Alabama or Wisconsin, a test result is the smaller problem. And a seller that markets around testing is telling you what kind of buyer it's courting. That alone is reason enough to stop taking its other claims seriously.
6. "Pharmaceutical grade" or "clinically proven"
"Pharmaceutical grade" implies a standard that doesn't exist here. With no FDA-approved 7-OH drug, there's no approved product for anything to be graded against. The phrase borrows the credibility of medicine without any of its review.
"Clinically proven" is worse, because it implies a health claim. FDA's July 15, 2025 warning letters to seven companies treated some 7-OH products as unapproved new drugs with unproven claims. A health claim on a 7-OH product doesn't make it more trustworthy. It's a regulatory problem printed on the label.
The FTC's Health Products Compliance Guidance, issued December 20, 2022, says the agency generally expects high-quality randomized, controlled human clinical trials behind health claims. FDA has already called the health claims in its 7-OH warning letters unproven. So a "clinically proven" badge in this category deserves no weight at all.
What's left to compare once the claims are gone?
Not much, and that's the point. What survives is checkable. Is the product lawful where you live? Is there a batch COA with a matching lot number, from a lab listed in a public accreditation directory? Everything else on the page is marketing.
One limit applies. Nothing here can predict how DEA would measure a product sitting close to the threshold, since the October notice names no test method and doesn't explain what happens to ND results. But a seller whose page relies on the six claims above has already answered the more basic question for you.
